

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of the Claims:**

Claims 1-21 (canceled).

22 (currently amended). A method of treating an infection of the lower respiratory tract, comprising administering to a patient in need thereof ~~an amount of liposomes sufficient to treat the infection, said liposomes containing povidone iodine in an amount sufficient to treat the infection.~~

Claims 23-31 (canceled).

32 (previously presented). The method according to claim 22, wherein the liposomes have a diameter in the range from about 1  $\mu\text{m}$  to about 50  $\mu\text{m}$ .

33 (previously presented). The method according to claim 32, wherein the liposomes have a diameter in the range from 20  $\mu\text{m}$  to 30  $\mu\text{m}$ .

Claims 34-35 (canceled).

36 (previously presented). The method of claim 22, wherein the liposomes further contain an anesthetically active agent.

37 (previously presented). The method of claim 22, wherein the liposomes further contain a pharmaceutically acceptable additive.

38 (previously presented). The method of claim 22, wherein the administration is by inhaling the liposomes.

39 (previously presented). The method of claim 22, wherein the liposomes are in the form of a powder, a spray, an emulsion or a dispersion.

40 (previously presented). The method of claim 32, wherein said liposomes contain between 0.1 to 10%, by weight, povidone iodine.

41 (previously presented). The method of claim 40, wherein the liposomes have a diameter in the range from 20  $\mu\text{m}$  to 30  $\mu\text{m}$ .

Claims 42-50 (canceled).

51 (previously presented). The method of claim 22, wherein the liposomes have a diameter in the range from about 1  $\mu\text{m}$  to 30  $\mu\text{m}$ .

Claims 52-54 (canceled).

55 (previously presented). The method of claim 22, wherein the liposomes have a diameter in the range from 10  $\mu\text{m}$  to 20  $\mu\text{m}$ .

56 (previously presented). The method of claim 22, wherein the liposomes have a diameter in the range from 1  $\mu\text{m}$  to 6  $\mu\text{m}$ .

57 (previously presented). The method of claim 22, wherein the liposomes have a diameter in the range from 2  $\mu\text{m}$  to 5  $\mu\text{m}$ .

58 (previously presented). The method of claim 22, wherein said liposomes comprise a liposome membrane forming substance that is present in an amount between 1 to 5%, by weight, of the liposomes.

59 (previously presented). The method of claim 22, wherein said liposomes are lecithin liposomes.

60 (previously presented). The method of claim 40, wherein said liposomes comprise a liposome membrane forming substance that is present in an amount between about 1 to 5%, by weight, of the liposomes.

61 (previously presented). The method of claim 40, wherein said liposomes are lecithin liposomes.

Claims 62-63 (canceled).

64 (previously presented). The method of claim 40, wherein said liposomes contain about 0.1% to 2% by weight of povidone iodine.

65 (currently amended). The method of claim 22, wherein the infection is in the trachea trachea.

66 (previously presented). The method of claim 22, wherein the infection is in the bronchi.

67 (previously presented). The method of claim 22, wherein the infection is in the alveoli.

68 (previously presented). The method of claim 22, wherein the liposomes further contain a corticosteroid.

Claims 69-70 (canceled).

71 (previously presented). The method of claim 22, wherein the liposomes further contain an antibiotic.

72 (previously presented). The method of claim 22, wherein said liposomes further contain dexpanthenol, an allantoin, an azulene, a tannine, or a vitamin B compound.

73 (previously presented). The method of claim 22, wherein the infection is a bacterial, fungal, or viral infection.

74 (previously presented). The method of claim 22, wherein the patient is human.